Diana Castro
Neurology with Special Qualifications in Child Neurology · Denton, TXNPI 1750554689
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $249,632 of the $343,438 with a category attached, or 72.7%. 25 manufacturers reported payments, led by Biogen at 35.0% of the total. Reporting peaked in 2022 at $80,659 and has fallen 54.0% since, to $37,117 in 2025. Among neurology with special qualifications in child neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 286 payments — averaging $1200.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$120K
- Sarepta Therapeutics, Inc.$62K
- PTC Therapeutics, Inc.$58K
- Genentech USA, Inc.$29K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$21K
- Genentech, Inc.$11K
- plus $41K from 19 others
Across 165 payments — averaging $15,001 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$1.3M
- CSL Behring$495K
- Sarepta Therapeutics, Inc.$404K
- Genentech, Inc.$98K
- Argenx US, Inc.$66K
- Takeda Pharmaceuticals U.S.A., Inc.$64K
- plus $74K from 3 others
What the payments were for
- Consulting fees$249,63273%
- Speaking & faculty fees$74,42122%
- Travel & lodging$12,1464%
- Food & beverage$6,8242%
- Education$4140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 81 | $120,265 |
| Sarepta Therapeutics, Inc. | 54 | $62,403 |
| PTC Therapeutics, Inc. | 38 | $58,165 |
| Genentech USA, Inc. | 21 | $29,333 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 26 | $20,853 |
| Genentech, Inc. | 13 | $11,192 |
| Pfizer | 5 | $9,297 |
| ITF Therapeutics LLC | 6 | $8,842 |
| Novartis | 8 | $8,133 |
| Catalyst Pharmaceuticals, Inc. | 7 | $3,766 |
| Johnson & Johnson | 1 | $2,820 |
| Janssen Research & Development, LLC | 1 | $2,750 |
| NS Pharma, Inc. | 6 | $1,904 |
| F. Hoffmann-la Roche AG | 1 | $1,566 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,510 |
| AstraZeneca | 1 | $175 |
| Grifols USA, LLC | 4 | $98 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Sanofi | 3 | $71 |
| Argenx US, Inc. | 2 | $69 |
| Samsung HME America, Inc. | 1 | $50 |
| Boston Scientific | 1 | $33 |
| Grifols Shared Services North America, Inc. | 1 | $31 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| CSL Behring | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$343,438 in reported general payments places this provider in the 95th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvrysdiRisdiplam | 27 | $735,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Evrysdi | $29,333 | $735,67227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
Other neurology with special qualifications in child neurology in Denton
- Roy EltermanDallas$5.9M
- Huda ZoghbiHouston$5.5M
- Shade MoodyHouston$194K
- Mary Kay KoenigHouston$171K
- Michael PerryFort Worth$162K
- Raphael SchiffmannDallas$88K
- Mauricio Delgado-AyalaDallas$75K
- Kaitlin BatleyDallas$74K
- Warren MarksFort Worth$58K
- Daniel GossettDallas$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.